financetom
Business
financetom
/
Business
/
Nvidia Stock Is Down Nearly 20% YTD: What's Going On?
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Nvidia Stock Is Down Nearly 20% YTD: What's Going On?
Apr 2, 2025 12:56 PM

NVIDIA Corp ( NVDA ) shares have fallen 19.6% year to date, pressured by ongoing concerns about AI spending, trade restrictions and broader market weakness. The stock, which was one of the best-performing names in 2024, has struggled in 2025 as investors reassess growth expectations and adjust to an increasingly uncertain economic environment.

What To Know: Restrictions on chip exports to China remain a major headwind for Nvidia ( NVDA ), raising concerns about the company’s ability to maintain its strong revenue growth. The company relies on China as a key market for its AI chips and any disruption in sales could have a material impact. Recent reports indicate that China is ramping up efforts to reduce its dependence on U.S. technology, which could further hurt Nvidia’s long-term positioning.

AI spending, which drove Nvidia's ( NVDA ) massive stock surge last year, is now under increased scrutiny. Some analysts are warning that corporations could slow their AI infrastructure investments in response to economic uncertainty.

Q1 Earnings: Nvidia's ( NVDA ) latest earnings report helped accelerate the downside momentum in shares. Revenue jumped 78% year-over-year and earnings per share climbed 71%. The company guided for first-quarter revenue of $43 billion, significantly higher than the $26.04 billion reported in the same quarter last year. Despite these numbers, the stock has continued to decline as investors focus more on macroeconomic risks and shifting sentiment around AI-related spending.

Market Overview: The broader semiconductor sector is also facing challenges. Advanced Micro Devices Inc. ( AMD ) is down 14.9% year-to-date, Broadcom Inc. ( AVGO ) has fallen 28% and Marvell Technology Inc. ( MRVL ) is down 44.5%. Nvidia's ( NVDA ) premium valuation has become less of a talking point as market conditions shift. The stock currently trades with a forward price-to-earnings ratio of approximately 24.5, which remains above some of its peers, but is down significantly from the peak.

U.S. President Donald Trump is set to announce reciprocal tariffs on several countries at 4 p.m. ET. The Trump administration has said the tariffs could target specific sectors.

NVDA Price Action: Nvidia ( NVDA ) shares were down 0.52% at $109.57 at the time of publication Wednesday, according to Benzinga Pro.

Read Next:

Wall Street Rebounds Ahead Of Tariff Announcement, Small Caps Rally, Bitcoin Hits $87,000: What’s Driving Markets Wednesday?

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Centene Confirms Receipt of Unsolicited Mini-Tender Offer From TRC Capital
Centene Confirms Receipt of Unsolicited Mini-Tender Offer From TRC Capital
Aug 21, 2025
04:46 AM EDT, 08/21/2025 (MT Newswires) -- Centene ( CNC ) said Wednesday it has received an unsolicited mini-tender offer from TRC Capital Investment for the purchase of up to 4 million of its shares at $24.75 apiece. The company urged its stockholders to reject the offer, saying that it is below the current market price of its shares. It...
Johnson & Johnson to invest $2 billion to boost US manufacturing as drug tariffs loom
Johnson & Johnson to invest $2 billion to boost US manufacturing as drug tariffs loom
Aug 21, 2025
(Reuters) -Johnson & Johnson ( JNJ ) committed to invest $2 billion in North Carolina on Thursday to expand the drugmaker's U.S. manufacturing presence as potential drug import duties from President Donald Trump's administration loom. J&J said it plans to build a new facility at Tokyo-based Fujifilm Diosynth's manufacturing site in Holly Springs, North Carolina, over the next 10 years....
Alvotech Says European Commission Approved Mynzepli to Treat Retinal Diseases
Alvotech Says European Commission Approved Mynzepli to Treat Retinal Diseases
Aug 21, 2025
05:29 AM EDT, 08/21/2025 (MT Newswires) -- Alvotech ( ALVO ) and UK-based Advanz Pharma said Thursday that their Mynzepli fusion protein was approved by the European Commission to treat retinal diseases, including neovascular age-related macular degeneration. The companies said the approval was based on non-clinical and clinical similarity data, which included a confirmatory efficacy study comparing Mynzepli with Bayer's...
Yatsen Reports Q2 Adjusted Earnings, Higher Revenue; Q3 Sales Outlook Set
Yatsen Reports Q2 Adjusted Earnings, Higher Revenue; Q3 Sales Outlook Set
Aug 21, 2025
05:25 AM EDT, 08/21/2025 (MT Newswires) -- Yatsen Holding ( YSG ) reported Q2 non-GAAP earnings Thursday of 0.13 Chinese renminbi ($0.02) per diluted American depositary share, swinging from a loss of 0.67 renminbi a year earlier. Analyst estimates were not readily available for comparison. Net revenue for the quarter ended June 30 was 1.09 billion renminbi, compared with 794.5...
Copyright 2023-2026 - www.financetom.com All Rights Reserved